Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 31;13(11):2725. doi: 10.3390/cancers13112725

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Course of disease, treatment, and morpho-molecular workup of patient 1. (A) Timeline. (B) Histology of the primary tumor, including NRAS Q61R immunohistochemistry (inserts); left: KRAS mutant region, middle: KIT mutant region, right: NRAS mutant region; PET MIP display and fused PET/CT image at primary diagnosis. (C) T1-weighted contrast-enhanced and fat-suppressed MR image at local progression (long arrows: sinonasal tumor mass, short arrows: intraorbital extraconal tumor mass, arrowheads: dural enhancement. (D) MR image at local regression (arrows/arrowheads: see above), histology of the liver biopsy, including NRAS Q61R immunohistochemistry (insert); PET MIP display and fused PET/CT image before liver biopsy. (E) Histology of the soft tissue metastasis, including NRAS Q61R immunohistochemistry (insert); PET MIP display and fused PET/CT image at progression under kinase inhibitors. Scale bar: 40 µm. wt: wild type.